On April 25, 2024, NeuroSense Therapeutics Ltd., closed the transaction. The transaction included participation from single investor. As a part of the transaction, the company paid CAD 50,000 cash fee and 70,964 of the ordinary shares of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 USD | +9.80% |
|
+24.72% | +42.68% |
06-24 | Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm... | ![]() |
06-24 | NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.68% | 20.2M | |
+15.20% | 121B | |
+19.67% | 113B | |
+17.23% | 26.02B | |
-23.86% | 19.39B | |
-19.19% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- NRSN Stock
- News NeuroSense Therapeutics Ltd.
- NeuroSense Therapeutics Ltd. announced that it has received $4.47 million in funding